{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:32:11Z","timestamp":1786649531154,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>A 30-year-old male presented with a mass in the gallbladder fossa infiltrating the liver, abdominal lymph nodes, port site lesion, and peritoneal nodularity, with a prior history of laparoscopic cholecystectomy. Cytology from the gallbladder fossa mass and port site intercostal lesion revealed features of adenocarcinoma. The patient was treated with six cycles of modified gemcitabine and oxaliplatin based chemotherapy, which resulted in complete metabolic response. The patient underwent extended cholecystectomy and wide local excision of the port site lesion. The patient had pathologic response with minimal microscopic residual disease of &lt;1 mm size infiltrating liver. The patient received adjuvant chemoradiation. The patient is in remission at 4.1 years after the diagnosis of cancer. Resection with chemotherapy and radiotherapy can be considered if the metastatic lesions are isolated to prolong survival in gallbladder cancer.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_412_24","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:00:28Z","timestamp":1751713228000},"page":"720-724","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Gallbladder cancer in a young male: An insight into an integrative approach for improving survival"],"prefix":"10.4103","volume":"21","author":[{"given":"Puja","family":"Sahai","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aprajita","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilasha","family":"Yadav","sequence":"additional","affiliation":[{"name":"Pathology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanuman P.","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Pathology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saggere M.","family":"Shasthry","sequence":"additional","affiliation":[{"name":"Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viniyendra","family":"Pamecha","sequence":"additional","affiliation":[{"name":"Hepatopancreat Obiliary and Liver Transplant Surgery, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"R1-20250707","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cgh.2017.08.017","article-title":"Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers","volume":"16","author":"Torre","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R2-20250707","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00534-006-1187-0","article-title":"Aggressive surgery for stage IV gallbladder carcinoma;what are the contraindications?","volume":"14","author":"Nishio","year":"2007","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"R3-20250707","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/SLA.0000000000002385","article-title":"Surgical management of gallbladder cancer:Simple versus extended cholecystectomy and the role of adjuvant therapy","volume":"266","author":"Kasumova","year":"2017","journal-title":"Ann Surg"},{"key":"R4-20250707","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1477-2574.2012.00544.x","article-title":"Role of radical surgery in patients with stage IV gallbladder cancer","volume":"14","author":"Kang","year":"2012","journal-title":"HPB (Oxford)"},{"key":"R5-20250707","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3857\/roj.2021.00717","article-title":"Reviewing the potential role of radiation therapy in gallbladder cancer:An update","volume":"40","author":"Kumar","year":"2022","journal-title":"Radiat Oncol J"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809:A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1245\/s10434-024-15117-y","article-title":"Adjuvant chemoradiation in resected biliary adenocarcinoma:Evaluation of SWOG S0809 with a large national database","volume":"31","author":"Dominguez","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"R8-20250707","doi-asserted-by":"crossref","first-page":"43","DOI":"10.21037\/cco.2019.07.05","article-title":"Systemic therapy of gallbladder cancer:Review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer","volume":"8","author":"Azizi","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"R9-20250707","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","article-title":"Modified gemcitabine and oxaliplatin or gemcitabine +cisplatin in unresectable gallbladder cancer:Results of a phase III randomised controlled trial","volume":"123","author":"Sharma","year":"2019","journal-title":"Eur J Cancer"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_412_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:55:05Z","timestamp":1786647305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_412_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_412_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-02-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}